Ranjana Advani, MD, recently published findings from the anti-CD47 lymphoma study at Stanford. This phase 1 trial tested Hu5F9-G4 in combination with rituximab in patients with non-Hodgkins Lymphoma. Half of the 22 people enrolled had a positive response to the therapy, and about one-third went into complete remission from their cancer.
Dr. Advani is the PI for the study (sponsor: Forty Seven Inc) and is the lead author for the publication in the New England Journal of Medicine.
Kudos to Dr. Advani and her team in the Lymphoma group for your hard work on this clinical trial!